Free feasibility study

Have a target in mind?

Send us the antigen and we will come back with our assessment, at no cost and with no commitment.

Where do you start?

You have an antigenYou have an antigen you need to target, with or without an epitopeYou already have antibody candidatesTell us about your candidates and your objective. Sequences are shared later, under a confidentiality agreement.

Go to the form

Nanobody discovery

VHH from your antigen

Designed de novo against your target dynamics. In 6 weeks.

From your antigen to designed sequences.: 6 weeks
To wet-lab validation of the candidates.: 9 weeks

How it works

123456789
FeasibilitydaysFree
We score your antigen and the site you want to engage, and return a compatibility verdict. Free.
Prototypingweek 1
A short scoping run on your actual target: we design the workflow it needs and size the generative campaign, so the quote reflects your target rather than an average one.
Generative designweeks 2–4
Binders generated against the chosen site on a clinically precedented scaffold, under developability constraints
Computational triageweeks 4–5
Filters on sequence liabilities, structure and independent re-prediction narrow the output to 50 to 200 candidates worth looking at closely
Molecular dynamicsweeks 5–6
The shortlist is pre-validated dynamically: we watch the complex hold, or fail to hold, before anything is expressed
Wet-lab validationweeks 7–9
Best candidates expressed and tested: binding, expression, behaviour in solution

You approve each stage before the next one starts.

What you get

Ranked candidate sequences, each with the epitope it engages.
A developability profile per candidate: aggregation, expression and specificity, assessed during design rather than discovered later.
Binding data from the laboratory for the candidates we take forward.
The design record: how each candidate was produced, ready for your files and your counsel.
Full ownership. The sequences, the data and the intellectual property are yours.

What we need to start

The antigen sequence is enough. A structure helps, and if the epitope is defined by a published antibody, its PDB entry is usually all we need. Tell us the format you want downstream (VHH, VHH-Fc, bispecific, fusion) and what affinity and species cross-reactivity your programme requires.

The feasibility study is free in every case, and the quotation follows it rather than preceding it.

Read the Nanobody discovery page Go to the form

Your antigen required

A name or a public identifier such as a UniProt accession or a PDB code is enough.

Confidential sequences are exchanged later, under a confidentiality agreement.

What the binder has to do optional

If you know the site, tell us. If you do not, that is part of what the study addresses.

What challenges are you facing on this project? optional

For example: a target that resists immunisation, a patent to design around, poor developability.

About you

Your name required

Your company required

Your role required

E-mail required

We send the assessment to this address.

How did you hear about us? optional

Book a meeting

Philippe Herman, CEO, reads your request and replies by e-mail.

Prefer to talk first? Talk to us: 30 minutes with the Immunochem team.